Sep. 09, 2022
Dr. Weichang Zhou, CTO of WuXi Biologics: Secure the Future of Bioprocessing
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- CareersAbout Us
- InvestorsAbout Us
- News & MediaAbout Us
Perspectives
-
-
Sep. 06, 2022Media Insights: How to leverage advancing technologies and enable innovation rapidly and cost-effectively? -
Jul. 06, 2022Media Insights: Dr. Jijie Gu, CSO of WuXi Biologics, Comments on BsAbs R&D Trend -
May. 11, 2022What’s the key to being a leader in the industry? -
Mar. 04, 2022The Watershed Moment for ADCs has Arrived -
Dec. 15, 2021The benefits of using a single-source for discovery, development and GMP manufacture of antibody drug conjugates and other novel bioconjugates -
Dec. 01, 2021Streamline the ADC Path to the Clinic with One-stop Drug Development and Critical Technology Advancements -
Dec. 29, 2020Applications and Impact of CRISPR/Cas9 in Bioprocessing -
Sep. 16, 2020Reducing Fill Risk in Drug Product Manufacture Utilizing New State-of-the-Art Systems and Platforms
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?